Researchers from Novozymes Biopharma and Malvern Instruments have been collaborating using light scattering techniques to demonstrate the short- and long-term stability of the novel recombinant human albumins Albucult and Recombumin.
These rAlbumins have been developed and optimised to deliver a safe, stable and regulatorycompliant product for therapeutic formulations.
The teams applied the resolving and detection capabilities of size exclusion chromatography light scattering (SEC-LS) and dynamic light scattering (DLS) offered by Malvern systems to monitor the stability of these Novozymes products.
The work is described in an article ‘Tools for evaluating the stability of human recombinant albumins used in human therapeutics’. See: www.malvern.com/formulationdevelopment

